Axsome Therapeutics, Inc.
AXSM
Classement en actions
#2380
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Prix de l'action
$157.20
Capitalisation boursière
$8.23B
Changement (1 jour)
-1.49%
Changement (1 an)
19.64%
Pays
US
Échange Axsome Therapeutics, Inc. (AXSM)
Catégorie
Healthcare
Revenus pour Axsome Therapeutics, Inc. (AXSM)
Revenus en Jun 2026 TTM : $776.57M
Selon les derniers rapports financiers de Axsome Therapeutics, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $776.57M. En 2023, l'entreprise a réalisé un chiffre d'affaires de $270.60M une augmentation par rapport à le chiffre d'affaires de l'année 2022, qui était de $50.04M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Axsome Therapeutics, Inc. de 2013 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $776.57M | 101.34% |
| 2024 | $385.69M | 42.53% |
| 2023 | $270.60M | 440.80% |
| 2022 | $50.04M | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | 1,525.65% |
US
|
|
| $2.23B | 186.90% |
US
|
|
| $15.74B | 1,927.42% |
AU
|
|
| $6.02B | 675.37% |
NL
|
|
| - | - |
CH
|
